Cargando…

Editorial: Therapeutic drug monitoring and clinical toxicology of anti-cancer drugs

Detalles Bibliográficos
Autores principales:	Liu, Yao, Martin, Jennifer H., Yan, Miao
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9641299/ https://www.ncbi.nlm.nih.gov/pubmed/36387188 http://dx.doi.org/10.3389/fonc.2022.1053211

Ejemplares similares

Editorial: Therapeutic drug monitoring and clinical toxicology of anti-cancer drugs, volume II
por: Yan, Miao, et al.
Publicado: (2023)

Recent developments in therapeutic drug monitoring and clinical toxicology
Publicado: (1992)

Analytical methods for therapeutic drug monitoring and toxicology
por: Xu, Quanyun A., 1961-
Publicado: (2011)

Editorial: New insights into the mechanisms of resistance to anti-cancer drugs
por: Bertoni, Francesco, et al.
Publicado: (2022)

Editorial: Anti-cancer drug delivery: lipid-based nanoparticles
por: Alkilany, Alaaldin M., et al.
Publicado: (2023)

Editorial: The toxicology of drugs of abuse
por: Ford, Benjamin M., et al.
Publicado: (2023)

Editorial: The effect of anti-cancer drug therapies in the treatment of lung cancer
por: Pisapia, Pasquale, et al.
Publicado: (2022)

Editorial: Metabolism of anti-cancer drugs: Interplay involving pharmacology and pharmacokinetics
por: Bapiro, Tashinga E., et al.
Publicado: (2022)

Therapeutic drug monitoring for cytotoxic anticancer drugs: Principles and evidence-based practices
por: Smita, Pattanaik, et al.
Publicado: (2022)

Editorial: Investigating drugs used off-label in various cancers
por: Liu, Wang, et al.
Publicado: (2023)

Editorial: Current Analytical Trends in Drug Testing in Clinical and Forensic Toxicology
por: Gallardo, Eugenia, et al.
Publicado: (2021)

Therapeutic Drug Monitoring of Tyrosine Kinase Inhibitors Using Dried Blood Microsamples
por: Verougstraete, Nick, et al.
Publicado: (2022)

Therapeutic drug monitoring in oncology - What’s out there: A bibliometric evaluation on the topic
por: Stojanova, Jana, et al.
Publicado: (2022)

Perspectives and Expertise in Establishing a Therapeutic Drug Monitoring Programme for Challenging Childhood Cancer Patient Populations
por: Barnett, Shelby, et al.
Publicado: (2022)

Voltage-Dependent Anion Channel 1 As an Emerging Drug Target for Novel Anti-Cancer Therapeutics
por: Shoshan-Barmatz, Varda, et al.
Publicado: (2017)

Editorial: Ubiquitin-Modifying Enzymes as Drug Targets and Biomarkers in Cancer
por: Bell, Jessica L., et al.
Publicado: (2021)

Editorial: Repurposed Drugs Targeting Cancer Signaling Pathways: Clinical Insights to Improve Oncologic Therapies
por: Pérez-Plasencia, Carlos, et al.
Publicado: (2021)

Editorial: Targeting metabolism of cancer cells and host to overcome drug resistance: Preclinical and clinical studies
por: Wang, Lishun, et al.
Publicado: (2023)

Antibody-drug conjugates: the clinical development in gastric cancer
por: Zhu, Yingze, et al.
Publicado: (2023)

Glutathione Peroxidase 4 as a Therapeutic Target for Anti-Colorectal Cancer Drug-Tolerant Persister Cells
por: Zhang, Xiaoli, et al.
Publicado: (2022)

Editorial: Recent advances of drug resistance research in colorectal cancer therapy
por: Ye, Chenyang, et al.
Publicado: (2022)

Editorial: Impact of Cancer Plasticity on Drug Resistance and Treatment in Solid Tumors
por: Cohen, Pascale A., et al.
Publicado: (2020)

Editorial: Drug resistance in breast cancer – mechanisms and approaches to overcome chemoresistance
por: Raman, Dayanidhi, et al.
Publicado: (2023)

Editorial: Enhancing Drug Delivery and Tumor Penetration
por: Tang, Yuxia, et al.
Publicado: (2021)

Editorial for the Special Issue: “Therapeutic Drug Monitoring of Antimicrobials”
por: Gijsen, Matthias, et al.
Publicado: (2022)

Editorial: Therapeutic Drug Monitoring in Solid Organ Transplantation
por: Staatz, Christine E., et al.
Publicado: (2021)

Editorial: Systemic immune dysregulation in malignant disease: Insights, monitoring and therapeutic exploitation
por: Christopoulos, Petros, et al.
Publicado: (2023)

Editorial: FDA-Approved Drug Repositioning for P-Glycoprotein Overexpressing Resistant Cancer
por: Yoon, Sungpil, et al.
Publicado: (2021)

Editorial: Transcriptional Regulation as a Key Player in Cancer Cells Drug Resistance
por: Martinez-Balibrea, Eva, et al.
Publicado: (2021)

Editorial: Drug-resistance in cancer cells: A new wine in an old bottle
por: da Fonseca, Leonardo Marques, et al.
Publicado: (2023)

Editorial: Biological aspects of targeted drug discovery: Development of novel targets and/or chemotherapies, and drug repurposing
por: Kalra, Rajkumar Singh, et al.
Publicado: (2022)

Editorial: Overcoming drug relapse and therapy resistance in NSCLC
por: Parakh, Sagun, et al.
Publicado: (2023)

Editorial: RNA recognition landscapes and anticancer drug targeting
por: Salvati, Erica, et al.
Publicado: (2023)

Editorial: Patient-derived tumor models for drug development
por: Sabaawy, Hatim E., et al.
Publicado: (2023)

Editorial: Novel targeted drugs for indolent lymphoid malignancies
por: Robak, Tadeusz, et al.
Publicado: (2023)

Clinical Perspective of FDA Approved Drugs With P-Glycoprotein Inhibition Activities for Potential Cancer Therapeutics
por: Lai, Jiun-I, et al.
Publicado: (2020)

Editorial: Advances in 3D cell culture for drug screening and toxicology evaluation
por: Tang, Jinglong, et al.
Publicado: (2023)

Editorial: Molecular Targets and Therapeutic Strategies in Gynecological Cancers
por: Lu, Ziwen, et al.
Publicado: (2022)

Editorial: Interaction Between Modern Radiotherapy and Novel Drugs in Prostate Cancer: Future Perspectives
por: Detti, Beatrice, et al.
Publicado: (2022)

COX-Independent Mechanisms of Cancer Chemoprevention by Anti-Inflammatory Drugs
por: Gurpinar, Evrim, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_fm6oignsbn2bdomtocbvr824d2